The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | First-line ibrutinib vs chemoimmunotherapy in CLL: a real-world data analysis
Lori Leslie, MD, Hackensack Meridian Mountainside Medical Center, Montclair, NJ, discusses clinical outcomes among real-world patients with chronic lymphoblastic leukemia (CLL) initiating first-line ibrutinib compared with chemoimmunotherapy. The study found that high-risk CLL patients treated with ibrutinib had significantly longer time to next treatment (TTNT) and required fewer lines of therapy than those treated with chemoimmunotherapy. Additionally, the study found that ibrutinib therapy provided substantial clinical benefit in patients with CLL regardless of risk status. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Lori Leslie, MD, has participated in a speaker bureau with Seattle Genetics, Celgene/BMS, KitePharma, BeiGene, Pharmacyclics/Janssen, AstraZeneca, Epizyme and Karyopharm; and has participated in an advisory board or done consultancy work with Bayer, Seattle Genetics, ADC therapeutics, Abbvie, Janssen, Pharmacyclics, Kite, AstraZeneca and TG Therapeutics.
